At a glance
| Abbreviation | RABV |
|---|---|
| ICTV species | Lyssavirus rabies |
| Family | Rhabdoviridae |
| Baltimore class | V — (−)ssRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: Rabies lyssavirus; Lyssavirus rabies
Riboviria › Negarnaviricota › Monjiviricetes › Mononegavirales › Rhabdoviridae › Lyssavirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Negarnaviricota |
| Class | Monjiviricetes |
| Order | Mononegavirales |
| Family | Rhabdoviridae |
| Subfamily | Alpharhabdovirinae |
| Genus | Lyssavirus |
| ICTV identifier | ICTV19710311 |
| NCBI taxon | 11292 |
| Exemplar isolate | M13215 |
Host evidence
- human: 879 GenBank records
- dog: 3,869 GenBank records
- cattle: 1,642 GenBank records
- cat: 113 GenBank records
- goat: 29 GenBank records (flagged for review)
- sheep: 28 GenBank records (flagged for review)
- horse: 18 GenBank records (flagged for review)
- water buffalo: 10 GenBank records (flagged for review)
- pig: 8 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
quote
According to the 2021 Global Health Estimates model, rabies causes 44 203 annual deaths.
quote
Once the virus infects the central nervous system and clinical symptoms appear, rabies is fatal in 100% of cases.
quote
The pooled incidence rate was 54.03 (95% CI: 43.92-64.13) per 100,000 population.
Lowest and highest vaccine effectiveness reported: 81% (Suntharasamai P 1986 Lancet; Rabies encephalitis after a bite from an animal with proven rabies, all ages, as treated) to 100% (Chutivongse S 1990 Lancet; Death from rabies after severe bite by proven rabid animal, all ages, as treated). Two of 2 estimates, each from its own study; not a summary figure.
- Controlled observational
What can follow the illness
quote
about 34 well-documented survivors, defined as survival at 6 months after onset of clinical rabies. ... Many have had serious neurological sequelae.
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Clinical description: when it is observed to begin
- Product label observation window
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Each figure is the one its source printed, with the sentence it came from. Nothing is recomputed, averaged or converted.
Severity
| Measure | As the source states it | Source |
|---|---|---|
| Case Fatality Ratio | 100%global | quoteOnce the virus infects the central nervous system and clinical symptoms appear, rabies is fatal in 100% of cases. Rabies fact sheet · source · verified 2026-10-30 |
More, with study designs and vaccine efficacy: disease-risk page.
Vaccines
Nothing in use found in the sources searched. That is not the same as nothing existing; see the methods page for what was searched.
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Sinovac rabies vaccine | Sinovac Biotech Co., Ltd | Not searched yet | Travel | Phase 3 | Not searched yet | NCT07416110 | candidateId ctgov-sinovac-rabies-vaccine-sinovac-biotech-co-ltd (targe |
| Sinovac Rabies Vaccine (Serum-free Vero Cell), Freeze-dried | Sinovac Biotech Co., Ltd | Not searched yet | Travel | Phase 3 | Not searched yet | NCT07055295 NCT07055880 | candidateId ctgov-rabies-vaccine-serum-free-vero-cell-freeze-dried-sin |
| Rabipur | GlaxoSmithKline | Not searched yet | Travel | Discontinued | Not searched yet | NCT03192371 | candidateId ctgov-rabipur-glaxosmithkline (targetDisease 'Rabies'); st |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Rabies vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “Rabies”
- Other Rhabdoviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose